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There is an urgent, global need for the develop-
ment of new antibacterial agents. We have ap-
plied the small-molecule macroarray approach
to the synthesis and screening of antibacterial
compounds active against the Gram-positive
pathogen Staphylococcus aureus. Several
macroarrays of 1,3-diphenyl-2-propen-1-ones
(chalcones), cyanopyridines, and pyrimidines
were synthesized on a planar cellulose support
system on the order of days. This support
system was found to be highly compatible
with antibacterial assay formats, including
disk-diffusion and agar-overlay visualization
methods. Further, sufficient compound was
isolated from each spot of the macroarray for
both compound characterization and minimum
inhibitory concentration (MIC) estimation. Anal-
ysis of the small-molecule macroarrays in these
assays uncovered a set of antibacterial agents
with in vitro MIC values against methicillin-
resistant S. aureus comparable to certain anti-
bacterial drugs in use today.
INTRODUCTION
The continued emergence of bacterial strains resistant to
antibacterial agents is a serious threat to human lives [1].
Each year, nearly two million patients in the United States
acquire bacterial infections in hospitals, and 10% of these
patients die as a result. Over 70% of these infections in-
volve bacteria that are resistant to at least one antibacte-
rial drug [2]. The Gram-positive pathogen Staphylococcus
aureus is possibly most notorious as a cause of these
infections due to the rapid appearance of multidrug-
resistant strains, including strains impervious tomethicillin
and the last-line therapy vancomycin [3]. For example,
only 1 year after U.S. Food and Drug Administration ap-
proval, S. aureus resistance emerged against oxazolidi-
nones (e.g., linezolid), the newest class of synthetic anti-
bacterials [1, 4]. Such a rapid growth of resistanceChemistry & Biology 14,underscores an urgent need for the continued develop-
ment of new antibacterial agents. Here, we report the dis-
covery of a suite of compounds that display potent anti-
bacterial activities against methicillin-resistant S. aureus.
In addition, we have identified, to our knowledge, a new
antibacterial structure class, 2-methyl-3-cyanopyridines.
These compounds were uncovered using the small-mole-
cule macroarray approach and serve to demonstrate the
utility of this technique for antibacterial research.
The continued need for new and structurally varied an-
tibacterial agents strongly supports a combinatorial ap-
proach for their synthesis [1, 4], and this is evidenced by
considerable research efforts in this area [5–7]. Our labo-
ratory has been engaged in the development of the
small-molecule macroarray as a tool for the rapid, parallel
synthesis of libraries of organic molecules (ca. 50–200
compounds) [8]. This method involves the spatially ad-
dressed, solid-phase synthesis of discrete small mole-
cules (mol wt % 500 g/mol) on planar cellulose supports
(spot size = 0.3 cm2). Macroarrays provide several advan-
tages relative to other combinatorial synthesis methods:
the arrays are inexpensive to prepare, straightforward
to manipulate, and yield sufficient compound per spot
for numerous assays to be performed postsynthesis
(100–200 nmol) [9–12]. We reasoned that these benefits
could significantly streamline the antibacterial discovery
process.
RESULTS AND DISCUSSION
Three complementary design criteria guided our synthesis
of macroarrays for antibacterial screening. First, we
sought to examine molecular scaffolds known to exhibit
antibacterial activity against S. aureus, as macroarrays
of such compounds would allow us to validate on- and
off-support antibacterial array screening formats. Second,
we also desired to study small-molecule classes that re-
main unexplored as antibacterials. Third, the synthetic
routes needed to be compatible with our planar solid-sup-
port system [8]. We selected three compound classes that
met these design criteria: 1,3-diphenyl-2-propen-1-ones
(chalcones), pyrimidines, and 2-methyl-3-cyanopyridines.
Certain lipophilic chalcones have been reported to exhibit
antibacterial activities against S. aureus [13, 14], whereas351–357, April 2007 ª2007 Elsevier Ltd All rights reserved 351
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Small-Molecule Macroarrays of Antibacterial AgentsFigure 1. Small-Molecule Macroarray Construction
(A) Macroarray synthesis. Reaction conditions: (a) hydroxyacetophenonesA–C, KOtBu, DMF, 80C, 10min (33); (b) benzaldehydes a–w, KOH, EtOH/
H2O (1:1), 80
C, 10 min (33); (c) cleavage: TFA vapor, then neutralization with NH3 vapor, room temperature, 2 hr; (d) 3-aminocrotononitrile, KOH,
EtOH, room temperature, 26 hr; (e) acetamidine- or guanidine-HCl, KOtBu, N,N-dimethyl acetamide, 80C, 36 hr. All reactions were performed
under air.
(B) Building blocks. Hydroxyacetophenones A–C (top) and benzaldehydes a–w (bottom) used in the construction of chalcone (3),
2-amino-3-cyanopyridine (5), and pyrimidine (7, 8) macroarrays.the latter two heterocycle classes have been largely un-
explored as antibacterial agents [15, 16]. We built upon
our previous macroarray synthesis methods and devel-
oped efficient synthetic routes to each structure class on
planar supports (Figure 1A) [10, 11]. These routeswere ap-
plied to the construction of 30- to 69-member macroar-
rays incorporating a broad range of functionality; the
building blocks utilized in macroarray synthesis are shown
in Figure 1B. Briefly, three hydroxyacetophenones (A–C)
were coupled in a spatially addressed manner to planar
cellulose derivatized with an acid-cleavable Wang linker
(1) [8]. Claisen-Schmidt condensation of support 2 with
various benzaldehydes (a–w) afforded chalcone macroar-
rays 3. Further condensation of these arrays (3) with352 Chemistry & Biology 14, 351–357, April 2007 ª2007 Elsevi3-aminocrotononitrile, acetamidine, or guanidine gave
2-methyl-3-cyanopyridine (5), methylpyrimidine (7), and
aminopyrimidine (8) macroarrays, respectively [17].
Liquid chromatography-mass spectrometry analyses of
a subset of the total compounds (70%) cleaved from the
macroarrays indicated good to excellent purities (ca.
70%–98%). Certain chalcone products (4) were isolated
as mixtures of cis and trans isomers, with the latter isomer
predominating (ca.R 4:1). As the double bond in certain
chalcones are labile to photoisomerization [13, 14], we
reasoned that separating these isomers prior to primary
screening would be unproductive. For the small number
of library members with lower purities, the major byprod-
uct was starting material and therefore a knowner Ltd All rights reserved
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Small-Molecule Macroarrays of Antibacterial AgentsFigure 2. Representative Antibacterial Assays Performed on Macroarrays and Active Compounds Identified
The strain used was S. aureus ATCC 10390. Scale: Petri dish diameter = 9 cm.
(A) Disk-diffusion assay performed on compound spots punched out from a cleaved chalconemacroarray (3) and vancomycin standard (loadings = 30
mg/spot). Zones of inhibition (in mm): 4Bl = 19; 4Bv = 22; 4Cf = <1; vancomycin = 20.
(B) Antibacterial compounds identified in assays conducted on macroarrays.
(C) Agar-overlay TTC assay of a cleaved 69-member chalcone macroarray (3) divided into six subarrays. The array building-block grid and com-
pounds displaying a range of activities are indicated.
(D) Agar-overlay TTC assay of compound 6Ao applied to planar cellulose in the shape of the federally registered University of Wisconsin, Madison
‘‘Motion W’’ logo.compound. Consequently, we deemed the macroarray
purity levels acceptable to proceed to antibacterial as-
says. The total time required for the synthesis of all four
macroarray classes was less than 2 days, highlighting
the efficiency of this synthetic approach for library con-
struction [8].
We first evaluated test chalcone macroarrays (3) in an-
tibacterial assays against S. aureus. Because the macro-
arrays were prepared on cellulose filter paper, we had
convenient access to the compounds in disk form for
standard disk-diffusion assays. Compound spots were
punched out of the macroarrays, subjected to vapor-
phase cleavage with acid (trifluoroacetic acid; TFA), and
neutralized (NH3) to afford disks containing ca. 30 mg of
adsorbed compound [8]. These disks were manually
placed on lawns of S. aureus, and zones of inhibition
were measured after an 18 hr incubation period. Using
this assay, we identified several chalcones (4) with anti-
bacterial activities against S. aureus, including two com-
pounds that were comparable on a per-microgram basisChemistry & Biology 14,to vancomycin and had novel structures (4Bv and 4Bl; Fig-
ures 2A and 2B) [13, 14]. However, this antibacterial assay
format had drawbacks: (1) the entire sample of compound
was consumed during the assay, and thus replicate arrays
needed to be synthesized to confirm activity and purity,
and (2) manipulating large numbers of compound disks
was relatively labor intensive.
We found that an agar-overlay assaywasmore effective
for the antibacterial screening of macroarrays relative to
disk diffusion. This assay format also took advantage of
the spatially addressed nature of the arrays (Figure 2C). In-
tact arrays were cleaved, overlaid with agar inoculated
with S. aureus, and incubated for an 18 hr period; treat-
ment thereafter with the redox indicator triphenyl tetrazo-
lium chloride (TTC) allowed clear and reproducible visual-
ization of areas of live (red) or dead (white) cells [18].
Antibacterial compounds generated an obvious white
spot, with sizes reflecting their relative activities and solu-
bilities. To reduce compound consumption in this assay,
we developed a technique to transfer macroarray351–357, April 2007 ª2007 Elsevier Ltd All rights reserved 353
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Small-Molecule Macroarrays of Antibacterial AgentsTable 1. Antibacterial Activity Data of Selected Macroarray Compounds against S. aureus
Entry Compound Purity (%)a,b
S. aureus Estimated
MIC Range (mM)c,d S. aureus MIC (mM)c,e MRSA MIC (mM)e,f
1 4At 94 25–50 21.2 ± 1.2 18.7 ± 1.2
2 4Be 88 25–50 21.0 ± 1.0 20.0 ± 1.0
3 4Bl 93 12.5–25 15.0 ± 0.5 15.0 ± 0.5
4 4Bo 91 <12.5 10.0 ± 1.0 10.0 ± 1.0
5 4Bv 88 <12.5 3.5 ± 0.5 3.0 ± 0.5
6 4Cf 86 >50 >250 >250
7 6Al 99 12.5–25 10.0 ± 0.5 10.0 ± 0.5
8 6Ao 99 <12.5 7.5 ± 1.2 7.5 ± 1.2
9 6Bt 99 <12.5 11.6 ± 0.9 13.4 ± 0.9
10 9Cf 86 25–50 32.5 ± 1.2 31.2 ± 1.2
11 Linezolid – – 10.0 ± 1.0 8.0 ± 1.0
12 Ciprofloxacin – – 0.6 ± 0.1 0.9 ± 0.1
a From HPLC analyses of crude macroarray compounds (UV detection at 254 nm).
bCertain chalcones 4 were mixtures of cis and trans isomers (on average 80% trans; see the Supplemental Data).
cS. aureus ATCC 10390.
d From serial dilution of spot stock solutions of crude macroarray compounds.
e From an authentic sample of the compound. Only trans isomers of chalcones 4were evaluated. Error reflects step size in the serial
dilutions.
fMethicillin-resistant S. aureus ATCC 33591 (MRSA).members onto multiple sheets by simply sandwiching
cleaved arrays between a solvent-saturated surface and
dry cellulose sheets (to generate up to eight copies simul-
taneously). The copies were then subjected to replicate
TTC assays or used for purity analysis.
Using this convenient transfer and overlay procedure,
we identified antibacterial chalcones and cyanopyridines
from test macroarrays 3 and 5 with a range of inhibitory
activities (e.g., 4Be and 4Bo; Figure 2C). This straightfor-
ward assay also revealed preliminary structure-activity re-
lationships,withchalcones (4) andcyanopyridines (6) bear-
ing multiple halogens at the -R2 position exhibiting the
highest activities. Pyrimidines 9 and 10 displayed only
low to moderate activities in this assay (see Figure S4 in
the Supplemental Data available with this article online).
In the course of these studies, we also found that the
TTC assay is compatible with small-molecule macroar-
rays in formats other than spots, as exemplified in
Figure 2D. We anticipate agar-overlay assays should
find broad application in macroarray-based research due
to their ease of use and versatility.
To acquire more quantitative antibacterial activity data
about our compounds and verify our on-support assay re-
sults, we performed solution-phase absorbance assays
that provided estimates of the minimum inhibitory con-
centration (MIC) of each macroarray member against
S. aureus. Stock solutions (ca. 2 mM) were generated by
cleaving and eluting 198 individual compounds from chal-
cone (3) and heterocyclic macroarrays (5, 7, and 8). The
stock solutions provided sufficient compound for esti-354 Chemistry & Biology 14, 351–357, April 2007 ª2007 Elsevmated MIC determination over a range of concentrations
(50–12.5 mM) in quadruplicate. The good overall purities
of the crude macroarray compounds allowed for reason-
able estimations of MICs.
The preliminary MIC assays revealed two chalcones
(4Bo and 4Bv) and two cyanopyridines (6Ao and 6Bt)
with estimated MICs of less than 12.5 mM against S. aureus
(Table 1). We resynthesized these active compounds in
solution, along with several other compounds that ex-
hibited varied levels of inhibition in these three assays
for comparison, and determined their actual MIC values.
(Note: all chalcones 4 were isolated and screened as the
single trans isomer.) The absolute and relative MIC values
compared favorably with our primary screening data
(Table 1). Furthermore, this set of compounds exhibited
analogous activities against a methicillin-resistant clinical
strain of S. aureus. Notably, four compounds (4Bo, 4Bv,
6Al, and 6Ao) were identified that displayed MIC values
against methicillin-resistant S. aureus comparable to
that of the current drug linezolid (entry 11), with chalcone
4Bv closer in activity to ciprofloxacin (entry 12). Evaluation
of these compounds in time-dependent bacterial killing
assays indicated different modes of activity for the two
structure classes, that is, chalcone 4Bv was found to be
bacteriostatic against S. aureus at its MIC, whereas cya-
nopyridine 6Ao was bactericidal (see the Supplemental
Data). Compounds with either mode of action are valuable
as antibacterial strategies [4]. To our knowledge, chal-
cones 4Bo and 4Bv were previously unknown to have ac-
tivity against S. aureus. Moreover, the discovery of 6Alier Ltd All rights reserved
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Small-Molecule Macroarrays of Antibacterial AgentsTable 2. Antibacterial Activity Data of Lead Compounds against Selected Susceptible Bacterial Pathogensa
Entry Compound S. epidermidis MIC (mM)b B. subtilis MIC (mM)b K. pneumoniae MIC (mM)b
1 4At 27.5 ± 2.5 27.5 ± 2.5 >250
2 4Be 22.5 ± 2.5 22.5 ± 2.5 40 ± 10
3 4Bl 12.5 ± 2.5 22.5 ± 2.5 >250
4 4Bo 12.5 ± 2.5 8.8 ± 1.2 >250
5 4Bv 3.8 ± 1.2 8.8 ± 1.2 NA
6 6Al 12.5 ± 2.5 6.3 ± 1.2 NA
7 6Ao 6.3 ± 1.2 3.8 ± 1.2 NA
8 6Bt 17.5 ± 2.5 22.5 ± 2.5 NA
9 9Cf >30 17.5 ± 2.5 NA
NA, not applicable.
aS. epidermidis ATCC 12228, B. subtilis subsp. spizizenii ATCC 6633, and K. pneumoniae ATCC 4352.
b From an authentic sample of the compound. Only trans isomers of chalcones 4were evaluated. Error reflects step size in the serial
dilutions.and 6Ao is significant, as 2-methyl-3-cyanopyridines rep-
resent, to our knowledge, a new antibacterial structure
class.
To broaden the potential utility of these lead com-
pounds as antibacterial agents, we examined their activi-
ties against a panel of bacterial strains. We selected the
following six pathogens due to their clinical relevance:
(1) Gram-negative: Pseudomonas aeruginosa, Escherichia
coli, Klebsiella pneumoniae, and Salmonella typhimurium,
and (2) Gram-positive: Staphylococcus epidermidis and
Bacillus subtilis. Previous reports have indicated that
chalcones are most effective against Gram-positive
bacteria [19], whereas the selectivities of 2-methyl-3-
cyanopyridines and pyrimidines are for the most part un-
known [15, 16]. To access rapidly the compounds’ activi-
ties, we performed agar-overlay TTC assays against the
panel of six strains. Briefly, we prepared arrays of our
nine active compounds in Table 1 by spotting 30 nmol al-
iquots of purified compound onto individual filter paper
sections, and subjected the arrays to TTC overlay assays
against each strain as described above. These experi-
ments revealed that the compounds were significantly
more active against the Gram-positive strains relative to
Gram-negative, with only K. pneumoniae being weakly
susceptible to chalcones 4At, 4Be, 4Bl, and 4Bo (see
Figure S5).
We determined MIC values for each active compound
against S. epidermidis, B. subtilis, and K. pneumoniae
(Table 2), and the MICs for the former two Gram-positive
strains closely matched those determined for S. aureus
(Table 1). Indeed, cyanopyridines 6Al and 6Ao and meth-
ylpyrimidine 9Cf displayed increased activities against
B. subtilis versusS. aureus (entries 6, 7, and 9, respectively;
Table 2). In accordance with the agar-overlay assays, the
MIC values against K. pneumoniae were considerably
higher, however. Together, these data indicate that the
lead compounds identified in this study represent both
a potent and selective family of antibacterials.Chemistry & Biology 14In summary, we have demonstrated the utility of the
small-molecule macroarray as a tool for the discovery of
antibacterial agents. Three complementary assay proto-
cols were developed that underscore the versatility of
the macroarray platform for antibacterial research. Rea-
sonably sized macroarrays were constructed and
screened in these assays on the order of days. Through
this work, we identified four compounds displaying in vitro
MIC values against methicillin-resistant S. aureus that rival
certain antibacterials in use today. Although these com-
pounds are in an early stage of development, ongoing re-
search is directed at determining their modes of action
and preparing second-generation macroarrays to further
optimize their potencies and pharmacological profiles.
SIGNIFICANCE
Staphylococcus aureus infections represent one of
the largest health threats in hospital and community
settings in the United States. The effectiveness of cur-
rent antibacterial agents against S. aureus has be-
come severely limited due to the rapid rise of bacterial
resistance. As resistant strains will only continue to
emerge, there is an urgent need for the development
of new antibacterial compounds. Combinatorial syn-
thesis approaches are poised to have an impact in
this area. Toward this end, we have applied the
small-molecule macroarray approach to the synthesis
and screening of new antibacterial agents effective
against S. aureus. Macroarrays of chalcones and het-
erocycles were constructed and subjected to a suite
of antibacterial assays conducted either on or off the
macroarray support. These studies revealed two chal-
cones and two 2-methyl-3-cyanopyridines with in vitro
MIC values against S. aureus comparable to those of
established antibacterial agents. Furthermore, these
compounds displayed similar activities against
a methicillin-resistant strain of S. aureus and, 351–357, April 2007 ª2007 Elsevier Ltd All rights reserved 355
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Small-Molecule Macroarrays of Antibacterial Agentsselectivity for certain Gram-positive bacteria. These
results are significant, as these lead compounds
were identified through the synthesis and analysis of
only 198 compounds in total. Further studieswill be re-
quired to establish the efficacy of these compounds in
vitro and in vivo. Overall, this work underscores the
utility of the small-molecule macroarray as a tool for
the identification of antibacterial agents.
EXPERIMENTAL PROCEDURES
Synthesis
Planar cellulose membranes were derivatized with a Wang-type linker
as previously described (loading = ca. 1.5 mmol/cm2) [11]. Macroarrays
3, 5, 7, and 8 were synthesized according to modified procedures
[10, 11]. Compounds displaying a range of antibacterial activities
(Table 1) were resynthesized in solution using standard procedures
and fully characterized (purities R 98%); see the Supplemental Data
for full synthetic details.
Bacteriological Assays
Bacteriological work was performed with strains obtained from the
American Type Culture Collection (ATCC). Luria-Bertani (LB) medium
was used, as directed, for all bacterial work and was solidified with
agar as needed. Overnight cultures were grown at 37C with shaking
(B. subtilis was grown at 30C).
Disk-Diffusion Assay
Compound spots were cleaved with TFA and neutralized with NH3 as
described in Supplemental Data. A 200 ml portion of diluted S. aureus
10390 (106 CFU/ml) was spread homogeneously across an agar plate.
Compound spots were placed onto the agar, the plate was incubated
at 37C for 18 hr, and the diameters of the zones of inhibition were
measured.
Agar-Overlay TTC Assay
Macroarray copies were generated using the array transfer protocol
described in the Supplemental Data. Warm agar (15 ml) containing
106 CFU/ml bacteria was poured into a Petri dish (9 cm diameter).
The dish was swirled to eliminate air bubbles, and a macroarray
copy (6 3 6 cm) was fully submerged in the agar. Following an 18 hr
incubation at 37C, the plates were flooded with 0.1% (w/v) TTC in
LB and allowed to develop for 1 hr to visualize the zones of inhibition.
Red zones indicated healthy bacteria, while white zones indicated
that a compound on the macroarray inhibited growth of the bacterial
strain [18].
MIC Determination
For estimatedMIC determination, dimethyl sulfoxide was added to the
dried compound residue obtained from a single spot to afford ca.
100 ml of a 2 mM stock solution. Aliquots (5 ml) of these solutions
were added to a 96-well plate, followed by 195 ml of diluted S. aureus
10390 (106 CFU/ml) to yield ca. 50 mM final concentrations. The plates
were swirled for 1 hr to ensure compound dissolution, incubated for
12 hr at 37C, and the absorbance at 595 nm was recorded using
a plate reader [5]. Compounds that showed complete growth inhibition
at ca. 50 mM (abs = 0.04) were subjected to further testing at lower con-
centrations (ca. 25 and 12.5 mM). Actual MIC values were determined
for lead compounds resynthesized in solution using an analogous pro-
cedure with solutions of known concentration (see the Supplemental
Data).
Supplemental Data
Supplemental data include eight figures and full details of all synthetic
and biological work and can be found with this article online at http://
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